Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Immunology
Prevalence
12000.0 / 100K
Incidence
1000.0 / 100K/yr
4 drugs in development·3 companies·3 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| xhance | Paratek Pharmaceuticals, Inc. (PRTK) |
Phase 3(1)
| Drug | Company |
|---|---|
| LY3650150 | ELI LILLY & Co (LLY) |
Compare drugs
Frequently asked questions
How many drugs are in development for Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)?
BioSniper tracks 4 drugs in development for Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) across 3 companies.
How many clinical trials target Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)?
There are 3 clinical trials targeting Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) tracked by BioSniper.
What is the prevalence of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)?
The estimated prevalence of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) is approximately 12000.0 per 100,000 population.
Deep-dive into Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis